Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Department of Neurology Translational Center for Excellence for Neuroepidemiology and Neurological Outcomes Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
BMC Neurol. 2024 Sep 6;24(1):325. doi: 10.1186/s12883-024-03830-w.
Deprescribing of potentially inappropriate medications is recommended for older adults and may improve health outcomes and quality of life in persons living with Parkinson disease (PD). Patient attitudes, beliefs, and preferences play a crucial role in the success of deprescribing interventions. We aimed to examine the attitudes and beliefs about medication burden and deprescribing among persons living with PD.
We administered a survey to participants of Fox Insight, a prospective longitudinal study of persons living with PD. The survey included the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire and additional questions about adverse drug effects. We used logistic regression models to explore potential predictors of treatment dissatisfaction and willingness to deprescribe.
Of the 4945 rPATD respondents, 31.6% were dissatisfied with their current medications, and 87.1% would be willing to deprescribe medications. Male sex was associated with a greater willingness to deprescribe (adjusted odds ratio [aOR] 1.62, 95% confidence interval [CI] 1.37-1.93). A greater belief that the medication burden was high or that some medications were inappropriate was associated with treatment dissatisfaction (aORs 3.74, 95% CI 3.26-4.29 and 5.61, 95% CI 4.85-6.50), and more willingness to deprescribe (aORs 1.74, 95% CI 1.47-2.06 and 2.87, 95% CI 2.41-3.42). Cognitive impairment was the adverse drug effect participants were most concerned about when prescribed new medications to treat nonmotor symptoms.
Persons with PD are often dissatisfied with their overall medication load and are open to deprescribing. Medications that are associated with cognitive impairment might be prioritized targets for deprescribing interventions in this population.
为老年人推荐潜在不适当药物的撤药,并可能改善帕金森病(PD)患者的健康结果和生活质量。患者的态度、信念和偏好在撤药干预的成功中起着至关重要的作用。我们旨在研究 PD 患者对药物负担和撤药的态度和信念。
我们向 Fox Insight 的参与者进行了一项调查,该研究是一项前瞻性纵向 PD 患者研究。该调查包括修订后的患者对撤药的态度(rPATD)问卷和关于不良药物反应的其他问题。我们使用逻辑回归模型探讨治疗不满和撤药意愿的潜在预测因素。
在 4945 名 rPATD 受访者中,31.6%对当前药物治疗不满意,87.1%愿意撤药。男性与更愿意撤药相关(调整后的优势比[aOR] 1.62,95%置信区间[CI] 1.37-1.93)。更高的药物负担或某些药物不适当的信念与治疗不满相关(aORs 3.74,95%CI 3.26-4.29 和 5.61,95%CI 4.85-6.50),并更愿意撤药(aORs 1.74,95%CI 1.47-2.06 和 2.87,95%CI 2.41-3.42)。认知障碍是参与者在开具新药物治疗非运动症状时最担心的不良药物作用。
PD 患者通常对其整体药物负荷不满意,并愿意撤药。与认知障碍相关的药物可能是该人群撤药干预的优先目标。